Lead Pharma has signed a collaboration and licence agreement with Roche for the development of oral small molecules to treat a broad range of immune-mediated diseases.
Immune-mediated disorders include joint diseases such as rheumatoid arthritis; skin diseases, including psoriasis and atopic dermatitis; as well as inflammatory bowel diseases.
Go deeper with GlobalData
According to the deal, Lead Pharma will get a €10m upfront payment and be eligible for research funding and pre-clinical milestone payments.
Total potential payments, including research, development, regulatory and sales milestones, may amount to €260m, in addition to royalties on worldwide sales.
The companies will jointly work in research activities up to the selection of a pre-clinical candidate. Later on, Roche will handle further development and global commercialisation.
The R&D partnership builds on Lead Pharma’s expertise in the discovery, design and optimisation of small-molecule treatments.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataLead Pharma CEO Frans van den Berg said: “Our ambition is to develop life-changing treatments for patients. We are delighted to team up with Roche to pursue this goal.
“Partnering is a key element of our strategy, this collaboration is yet another validation of the value of Lead Pharma’s innovation power.”
This is the second project Lead Pharma has partnered with a major pharma company under its Discover, Design and Deliver platform.
Roche Pharma Partnering global head James Sabry said: “We are committed to advancing innovative science and transformative medicines for people affected by different immune-mediated diseases.
“We are looking forward to further building on our expertise in this field and collaborating with Lead Pharma, aiming to make a difference for those patients.”
In 2015, Lead Pharma partnered with Sanofi to develop treatments for autoimmune disease.
